Volixibat
| CAS号 | 1025216-57-2 | 货号 | BCP24905 |
| 中文名 | Volixibat | ||
| 英文名 | Volixibat | ||
| 中文别名 | |||
| 英文别名 | LUM-002; LUM 002; LUM002; SHP-626; SHP 626; SHP626; SAR-548304; SAR548304; SAR 548304; | ||
| 分子式 | C38H51N3O12S2 | 分子量 | 805.96 |
| 生物活性 | Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH. Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. Also known as the ileal bile acid transporter (IBAT), ASBT is primarily responsible for the enterohepatic recirculation of bile acids and ultimately for hepatic lipid and glucose metabolism. Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in the liver have been implicated in its pathogenesis. According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments for NASH. | ||
| 信号通路 | Ion Channel/Membrane Transporter | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！